Small-Molecule Inhibitors of PARPs: From Tools for Investigating ADP-Ribosylation to Therapeutics

Over the last 60 years, poly-ADP-ribose polymerases (PARPs, 17 family members in humans) have emerged as important regulators of physiology and disease. Small-molecule inhibitors have been essential tools for unraveling PARP function, and recently the first PARP inhibitors have been approved for the...

Full description

Saved in:
Bibliographic Details
Published inCurrent topics in microbiology and immunology Vol. 420; p. 211
Main Authors Kirby, Ilsa T, Cohen, Michael S
Format Journal Article
LanguageEnglish
Published Germany 01.01.2019
Subjects
ADP-Ribosylation - drug effects
Drug Development
Humans
Poly(ADP-ribose) Polymerase Inhibitors - chemistry
Poly(ADP-ribose) Polymerase Inhibitors - pharmacology
Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use
Poly(ADP-ribose) Polymerases - metabolism
Polypharmacology
Online AccessGet more information

Cover

More Information
Summary:Over the last 60 years, poly-ADP-ribose polymerases (PARPs, 17 family members in humans) have emerged as important regulators of physiology and disease. Small-molecule inhibitors have been essential tools for unraveling PARP function, and recently the first PARP inhibitors have been approved for the treatment of various human cancers. However, inhibitors have only been developed for a few PARPs and in vitro profiling has revealed that many of these exhibit polypharmacology across the PARP family. In this review, we discuss the history, development, and current state of the field, highlighting the limitations and opportunities for PARP inhibitor development.
ISSN:0070-217X
DOI:10.1007/82_2018_137